Patients must not have any clinical evidence of congestive heart failure (CHF) (specifically, New York Heart Association [NYHA] class III [moderate] or class IV [severe]) at the time of registration; baseline echocardiogram within  days of registration must demonstrate an ejection fraction (EF) >= %; patients must have corrected QT (QTc) interval <  msec on prestudy electrocardiogram (EKG) and no known history of congenital long QT syndrome; patients must not have experienced unstable angina pectoris, clinically significant cardiac arrhythmias, or stroke (transient ischemic attack [TIA] or other ischemic event) within  months prior to registration and not have experienced myocardial infarction or thromboembolic event requiring anticoagulation within  months of registration; prestudy EKG must be obtained within  days prior to registration
History within  months prior to treatment of myocardial infarction, severe/unstable angina pectoris, coronary artery bypass grafting (CABG), New York Heart Association (NYHA) class III or IV congestive heart failure (CHF), stroke or transient ischemic attack (TIA)
History of a cerebral vascular event (stroke or transient ischemic attack), unstable angina, myocardial infarction, or cardiac symptoms consistent with New York Heart Association Class III-IV within  months prior to day  of protocol therapy
History of cerebral vascular event, unstable angina, myocardial infarction, or cardiac symptoms consistent with congestive heart failure within the last  months
Documented history of a cerebral vascular event (stroke or transient ischemic attack), unstable angina, myocardial infarction, or cardiac symptoms consistent with New York Heart Association (NYHA) Class III-IV (see Appendix .) within  months prior to their first dose of study drug.
Documented history of a cerebral vascular event (stroke or transient ischemic attack), unstable angina, myocardial infarction, or cardiac symptoms (including congestive heart failure) consistent with New York Heart Association Class III-IV within  months prior to the first dose of enfortumab vedotin.
Severe co-morbidity that would confer excess risk of surgery, radiation or chemotherapy, defined as follows:\r\n* Unstable angina and/or congestive heart failure within the last  months\r\n* Transmural myocardial infarction within the last  months\r\n* Evidence of recent myocardial infarction or ischemia by the findings of S-T elevations of >=  mm using the analysis of an electrocardiography (EKG) performed within  days of registration\r\n* New York Heart Association grade II or greater congestive heart failure requiring hospitalization within  months prior to registration\r\n* History of stroke, cerebral vascular accident (CVA) or transient ischemic attack within  months\r\n* Serious and inadequately controlled cardiac arrhythmia
History of myocardial infarction within  months before study entry, unstable congestive heart failure (New York Heart Association, NYHA Stage III-IV), angina pectoris, or transient ischemic attack or cardiac arrhythmia requiring medical therapy
Known cardiac disease including any of the following:\r\n* New York Heart Association (NYHA) grade II or greater congestive heart failure\r\n* History of myocardial infarction or unstable angina within  months prior to day \r\n* History of stroke or transient ischemic attack within  months prior to day 
Stroke, transient ischemic attack, unstable angina, myocardial infarction or congestive heart failure (New York Heart Association grade II or greater) within the past  months; unstable or severe intercurrent medical conditions, chronic renal disease, or uncontrolled diabetes mellitus
Active cardiac disease including any of the following:\r\n* New York Heart Association (NYHA) grade II or greater congestive heart failure\r\n* History of myocardial infarction or unstable angina within  months prior to day \r\n* History of stroke or transient ischemic attack within  months prior to day  of FOLFIRI + bevacizumab initiation
Participant has a documented history of a cerebral vascular event (stroke or transient ischemic attack), unstable angina, myocardial infarction, or cardiac symptoms consistent with New York Heart Association Class (NYHA) III - IV within  months prior to their first dose of study drug.
History within  months prior to treatment of myocardial infarction, severe/unstable angina pectoris, coronary artery bypass graft (CABG), New York Heart Association (NYHA) class III or IV congestive heart failure (CHF), stroke or transient ischemic attack (TIA)
Patients with a history of stroke, myocardial infarction, transient ischemic attack (TIA), severe or unstable angina, peripheral vascular disease, or grade II or greater congestive heart failure within the past  months are not eligible
Documented history of a cerebral vascular event (stroke or transient ischemic attack), unstable angina, myocardial infarction, or cardiac symptoms consistent with New York Heart Association (NYHA) Class III-IV within  months prior to their first dose of study drug
Documented history of a cerebral vascular event (stroke or transient ischemic attack), unstable angina, myocardial infarction, or cardiac symptoms consistent with New York Heart Association class III-IV within  months prior to their first dose of the study drugs
History (within the previous year) of stroke or transient ischemic attack, unstable angina, myocardial infarction, hospitalization for acutely decompensated congestive heart failure
Patients who have had a myocardial infarction, transient ischemic attack, unstable angina, or cardiovascular symptoms (CVS) within  months before treatment
Any of the following in previous  months: New York Heart Association (NYHA) class III/IV congestive heart failure, unstable angina, cerebrovascular accident (including transient ischemic attack), pulmonary embolism or myocardial infarction (by ECG or serologic criteria)
Uncontrolled intercurrent illness including infection, congestive heart failure, myocardial infarction, transient ischemic attack or stroke within  months; any such conditions that have occurred in the last  months but are no longer active at the time of registration are not considered exclusionary
Myocardial infarction, angina, congestive heart failure, cardiomyopathy, stroke or transient ischemic attack, chest pain or shortness of breath with activity, or other heart conditions being treated by a doctor.
Any history of major myocardial infarction, stroke or transient ischemic attack (TIA); minor acute myocardial infarction (AMI) and patients who have had cardiac bypass free of symptoms for at least  years may be eligible at the discretion of the study chair
History of a stroke or transient ischemic attack, unstable angina, myocardial infarction, or cardiac symptoms within  months prior to the first dose of treatment.
Documented history of a cerebral vascular event (stroke or transient ischemic attack), unstable angina, myocardial infarction, or cardiac symptoms consistent with New York Heart Association class III-IV within  months prior to their first dose of brentuximab vedotin
Have a history of congestive heart failure with a New York Heart Association class greater than , unstable angina, recent myocardial infarction (within  months of study enrollment), transient ischemic attacks, stroke, or arterial or venous vascular disease
Patients must not have recent (within six months) occurrence of myocardial infarction, unstable angina, stroke, transient ischemic attack, decompensated heart failure requiring hospitalization, or class III/IV heart failure
Active cardiovascular disease including any of the following:\r\n* New York Heart Association (NYHA) grade II or greater congestive heart failure\r\n* History of myocardial infarction or unstable angina within  months prior to day \r\n* History of stroke or transient ischemic attack within  months prior to day 
heart attack, acute ( days) cardiac event or stroke in preceding six months,
Patient must not have a history of stroke, myocardial infarction, transient ischemic attack (TIA), severe or unstable angina, peripheral vascular disease, or grade II or greater congestive heart failure =<  months prior to study entry
Unstable angina, myocardial infarction, known or suspected transient ischemic events, or stroke within  weeks of start of Screening.
